Where does Brent Ahrens work?

Brent Ahrens is General Partner at Canaan Partners and Board director at Transposon Therapeutics and Board director at Unchained Labs and Board director at EndoGastric Solutions.

What check size does Brent Ahrens write?

Brent Ahrens typically writes checks of $250K – $20M.

What boards does Brent Ahrens sit on?

Brent Ahrens holds tracked board seats at EndoGastric Solutions, Minimally Invasive Devices, Relievant Medsystems, Transposon Therapeutics, Unchained Labs.

What companies has Brent Ahrens invested in?

Investments tracked here include Abyrx, Calixa Therapeutics, Cerexa, Data Sciences International, DexCom, Durata Therapeutics, Elevation Pharmaceuticals, EndoGastric Solutions, Grey Wolf Therapeutics, Iterum Therapeutics, Orthocon, Inc., Pathios Therapeutics, and 8 more.

Where did Brent Ahrens go to school?

Brent Ahrens studied at The Tuck School of Business at Dartmouth (Master of Business Administration - MBA, Finance, Private Equity); University of Dayton (Master's degree, Mechanical Engineering); University of Dayton (Bachelor's degree, Mechanical Engineering).

Brent Ahrens

Investor

General Partner at Canaan Partners · Board director at Transposon Therapeutics · Board director at Unchained Labs · Board director at EndoGastric Solutions

Menlo Park, California

Writes $250K – $20M checks · typically $10M

Find your path to Brent

133 people in our graph share verified history with Brent — schools, employers, funds. One of them is your warm intro.

Julie WalkerunlockedBrent: together at Canaan Partners (2017–2019)

×3Brent: together at Canaan Partners

×5Brent: together at The Tuck School of Business at Dartmouth

Brent: together at Johnson & Johnson

About

Brent Ahrens, a longtime West Coast healthcare lead since 1999, uniquely combines deep biopharma and medtech investing with a Kauffman Fellows background and active mentorship of new VCs.

Contact· self-published, not guessed

b•••@canaan.comreveal

Likely email· guessed from name + firm domain, not firm-published

b•••@canaan.comreveal70% confident

Invests in

BiotechConsumerDeep TechEnterprise SoftwareFintechHardwareHealthtechMedical Devices

Board director at Transposon Therapeutics

Intro paths

→

In turn, Brent can intro founders to Transposon Therapeutics's investors below.

Transposon Therapeutics's investors · 1

Canaan PartnersStamford · $500K – $20M checks · since 2020

Board director at Unchained Labs

Intro paths

→

In turn, Brent can intro founders to Unchained Labs's investors below.

Unchained Labs's investors · 4

Canaan PartnersStamford · $500K – $20M checks · since 2015 CEI VenturesBrunswick · $1M – $4M checks TPGSan Francisco Tri-Valley VenturesPleasanton

Co-founders at Unchained Labs

Tim HarknessExecutive Officer, Director

Board director at EndoGastric Solutions

Intro paths

→

In turn, Brent can intro founders to EndoGastric Solutions's investors below.

EndoGastric Solutions's investors · 8

Accelmed PartnersMiami · since 2018 Canaan PartnersStamford · $500K – $20M checks · since 2015 De Novo VenturesBoston Evidity Health CapitalNew York · $5M checks FOUNDATION MEDICAL PARTNERSBoston Lightstone VenturesPortola Valley SightLine PartnersBloomington VCFA GroupNew York · $150K – $2.5M checks

Experience

Canaan PartnersGeneral Partnercurrent2005 — presentSan Francisco Bay Area
Canaan PartnersPrincipal1999 — 2004Menlo Park/SF
GSIDirector Business Development and Marketing1997 — 1999Cupertino, CA
Johnson & JohnsonEngineer1991 — 1995Cincinnati Metropolitan Area
IAP ResearchEngineer1986 — 1991Dayton Metropolitan Area

Deals · 5

Transposon TherapeuticsBoard seat

via Canaan Partners · filed Dec 2020 · $45.2M raise

Minimally Invasive DevicesBoard seat

via Canaan Partners · filed Nov 2015 · $14.1M raise

Unchained LabsBoard seat

via Canaan Partners · filed Jun 2015 · $31M raise

EndoGastric SolutionsBoard seat

via Canaan Partners · filed Apr 2015 · $1.5M raise

Relievant MedsystemsBoard seat

via Canaan Partners · filed Feb 2015 · $5M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Investor

AbyrxCalixa TherapeuticsCerexaData Sciences International DexComDurata TherapeuticsElevation PharmaceuticalsGrey Wolf Therapeutics Iterum Therapeutics Orthocon, Inc.Pathios TherapeuticsPeninsula PharmaceuticalsRevivantSemnur PharmaceuticalsSpinifex PharmaceuticalsThirtyFiveBio Limited

Sources: SEC Form D filings · the firm's website.

Colleagues at Canaan Partners

Antonio Lepore

Investor at Canaan Partners

Brendan Dickinson

General Partner at Canaan Partners

Bridget Flaherty

Director of Primary Labs at Primary Venture Partners

Colleen Cuffaro

Partner at Canaan Partners

Dana Malman Warren

Investor at Canaan Partners

Deepak Kamra

General Partner at Canaan Partners

Evan Teiger

Investor at Canaan Partners

Felipe Ossio

Investor at Canaan Partners

Network4

Brendan Dickinson

General Partner at Canaan Partners

Colleen Cuffaro

Partner at Canaan Partners

Deepak Kamra

General Partner at Canaan Partners

Guy Russo

General Partner at Canaan Partners

Investors connected to Brent in public investor directories — a warm-intro map.

Frequently asked questions

Who is Brent Ahrens?: Brent Ahrens, a longtime West Coast healthcare lead since 1999, uniquely combines deep biopharma and medtech investing with a Kauffman Fellows background and active mentorship of new VCs.
Where does Brent Ahrens work?: Brent Ahrens is General Partner at Canaan Partners and Board director at Transposon Therapeutics and Board director at Unchained Labs and Board director at EndoGastric Solutions.
What does Brent Ahrens invest in?: Brent Ahrens invests in Biotech, Consumer, Deep Tech, Enterprise Software, Fintech, Hardware, Healthtech, Medical Devices.
What check size does Brent Ahrens write?: Brent Ahrens typically writes checks of $250K – $20M.
What boards does Brent Ahrens sit on?: Brent Ahrens holds tracked board seats at EndoGastric Solutions, Minimally Invasive Devices, Relievant Medsystems, Transposon Therapeutics, Unchained Labs.
What companies has Brent Ahrens invested in?: Investments tracked here include Abyrx, Calixa Therapeutics, Cerexa, Data Sciences International, DexCom, Durata Therapeutics, Elevation Pharmaceuticals, EndoGastric Solutions, Grey Wolf Therapeutics, Iterum Therapeutics, Orthocon, Inc., Pathios Therapeutics, and 8 more.
Where did Brent Ahrens go to school?: Brent Ahrens studied at The Tuck School of Business at Dartmouth (Master of Business Administration - MBA, Finance, Private Equity); University of Dayton (Master's degree, Mechanical Engineering); University of Dayton (Bachelor's degree, Mechanical Engineering).